<DOC>
	<DOCNO>NCT02646800</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy intravenous micafungin treatment adult patient China infect Candida spp Aspergillus spp .</brief_summary>
	<brief_title>Post Marketing Study Evaluate Safety Efficacy Micafungin Against Fungal Infections Caused Candida Spp Aspergillus Spp</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Patients diagnose proven/probable/possible fungal infection cause Candida Aspergillus base Chinese guideline Females childbearing potential must negative pregnancy test within 48 hr prior study reliable method contraception start 4 week prior whole study . Patients capable understand purpose risk study , willing able participate study write date informed consent participate study obtain . Failure fulfill inclusion criterion another study , necessarily exclusion criterion study , assume inclusion criterion 14 state fulfil . Patient history hypersensitivity , serious reaction component product echinocandins . Subject unlikely comply visit schedule protocol opinion investigator history noncompliance . Pregnant woman , nurse mother , lactate woman , woman childbearing potential unwilling use reliable contraception duration study 6 week follow completion study . AST/ALT &gt; 5 time upper limit normal ( ULN ) Total bilirubin &gt; 2.5 time ULN Patient previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>Candidiasis</keyword>
	<keyword>Aspergillosis</keyword>
	<keyword>Antifungal</keyword>
</DOC>